On-Demand - Refractory Tourette Syndrome

Program Release: April 27, 2021 Expiration Date: April 27, 2023 *Recording of a live webinar originally held on 4/8/21 Estimated time to complete: 60 Minutes There are no prerequisites for participation Overview Achieving an effective treatment strategy for Tourette syndrome (TS) can be challenging in some cases, especially when associated co-morbidities or psychosocial factors influence disease manifestations. Since there is no current consensus on the definition of “refractory” TS, a framework of understanding “refractoriness” will be presented, including considerations related to proper diagnosis, symptom assessment, therapy dosing, adherence or side effects, and impact of co-occurring conditions and environmental influences. This case-based presentation will explore courses of action for clinicians to consider when symptom treatments in TS do not respond sufficiently to usual approaches. Guest Speaker Dr. Joohi Jimenez-Shahed Associate Professor of Neurology, Movement Disorders and Neurosurgery Ichan School of Medicine, Mount Sinai Dr. Jimenez-Shahed is an Associate Professor of Neurology and Medical Director, Movement Disorders Neuromodulation and Brain Circuit Therapeutics at the Icahn School of Medicine at Mount Sinai. After completing her undergraduate degree at Washington University in St. Louis, Dr. Jimenez-Shahed received her medical degree from Baylor College of Medicine (BCM) and Neurology residency training at Duke University Medical Center. She then completed a fellowship in Movement Disorders at the Parkinson’s Disease Center and Movement Disorders Clinical (PDCMDC) at BCM. Her research interests lie in investigating the intraoperative neurophysiology of patients undergoing deep brain stimulation (DBS) for movement disorders. Dr. Jimenez-Shahed serves as Chair of the Functional Neurosurgical Working Group of the Parkinson Study Group, and is the lead investigator for RAD-PD: a national quality improvement registry for patients undergoing DBS surgery for Parkinson’s disease. She is also an investigator with the Huntington Study Group, Dystonia Coalition and TSA International Database of DBS Studies in Tourette syndrome. She currently serves on the Science Advisory Board of the Davis Phinney Foundation and the Medical Advisory Board of the Tourette Association of America and has chaired the Medical Advisory Board for the Houston Area Parkinson Society. She has served as Principal Investigator for industry-sponsored and investigator-initiated clinical trials and has authored several papers and book chapters. She is the recipient of the Roy H. Cullen Quality of Life Award (Houston Area Parkinson Society), the Rising Star Clinician Award (BCM), the Fulbright & Jaworski L.L.P. Faculty Excellence Award in Teaching and Evaluation (BCM) and the Healthcare Heroes Award for Outstanding Health Care Practitioner (Houston Business Journal). She was recognized as a Woman of Excellence at BCM and is a 2018 graduate of the inaugural Women Leading in Neurology program of the American Academy of Neurology.